VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer

• Sponsor: Li Liu (Other)
• Overall Status: Unknown status
• CT.gov ID: NCT01891708
• Collaborator: (none)
• Enrollment: 40
• Location: 1
• Duration (Months): 66
• Patients Per Site Per Month: 0.6

Study Details

Study Description

Brief Summary

1. VEGFRs may be the biomarker which can predict the effect of bevacizumab in non small cell lung cancer

Condition or Disease	Intervention/Treatment	Phase
Non Small Cell Lung Cancer; Brain Metastasis	Other: bevacizumab, standard chemotherapy and radiation

Detailed Description

1. non small cell lung cancer (non squamous carcinoma)

2. ECOG 0-1

3. from 18-75 years old

Study Design

• Study Type: Observational [Patient Registry]
• Anticipated Enrollment: 40 participants
• Observational Model: Case-Only
• Time Perspective: Prospective
• Official Title: VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer
• Study Start Date: Jun 1, 2013
• Anticipated Primary Completion Date: Dec 1, 2014
• Anticipated Study Completion Date: Dec 1, 2018

Outcome Measures

Primary Outcome Measures

1. PFS [6 months]

Secondary Outcome Measures

1. OS [18 months]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 75 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• non squamous cell non small cell lung cancer

• with measurable disease

• ECOG 0-1

Exclusion Criteria:

• patients received surgery in recent 4 weeks

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	Hubei	China	430071

Sponsors and Collaborators

• Li Liu

Investigators

• Principal Investigator: Li Liu, MD, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Li Liu, Professor, Huazhong University of Science and Technology
• ClinicalTrials.gov Identifier: NCT01891708
• Other Study ID Numbers: XHZL02
• First Posted: Jul 3, 2013
• Last Update Posted: Jul 3, 2013
• Last Verified: Jul 1, 2013

• Additional relevant MeSH terms: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Brain Neoplasms; Bevacizumab

Study Results

No Results Posted as of Jul 3, 2013